We have reported that CDH3/P-cadherin is another TAA that is overexpressed in pancreatic cancer (Imai et al, 2008); however, it has been often observed that using a single TAA as a target of anticancer immunotherapy does not yield satisfactory therapeutic outcomes in animal models. This evidence concerns the gene CDH3 and familial pancreatic carcinoma.